Kinoxis Therapeutics

About:

Kinoxis Therapeutics is a biotechnology company that develops a range of novel therapeutic compounds.

Website: http://www.kinoxistherapeutics.com/

Twitter/X: kinoxis_tx

Top Investors: National Institutes of Health, University of Sydney, Brisbane Angels, Uniseed, UniSuper

Description:

Kinoxis Therapeutics is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstrating potent anti-addictive and prosocial effects in a number of different animal models and is progressing through pre-clinical testing.

Total Funding Amount:

$22.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Melbourne, Victoria, Australia

Founded Date:

2017-01-01

Founders:

Hugh Alsop, Michael Bowen

Number of Employees:

1-10

Last Funding Date:

2024-08-12

IPO Status:

Private

Industries:

© 2025 bioDAO.ai